key: cord-0260990-tk8cgpd7 authors: Grebe, E.; Yu, E. A.; Bravo, M. D.; Welte, A.; Bruhn, R. L.; Stone, M.; Green, V.; Williamson, P. C.; Feldstein, L. R.; Jones, J. M.; Busch, M. P.; Custer, B. title: COVID-19 vaccine effectiveness against SARS-CoV-2 infection in the United States prior to the Delta and Omicron-associated surges: a retrospective cohort study of repeat blood donors date: 2022-04-16 journal: nan DOI: 10.1101/2022.04.15.22273412 sha: b95d601669a698d3d23f7fad52ebf784252cc65a doc_id: 260990 cord_uid: tk8cgpd7 To inform public health policy, it is critical to monitor COVID-19 vaccine effectiveness (VE), including against acquiring infection. We estimated VE using a retrospective cohort study among repeat blood donors who donated during the first half of 2021, demonstrating a viable approach for monitoring of VE via serological surveillance. Using Poisson regression, we estimated overall VE was 88.8% (95% CI: 86.2-91.1), adjusted for demographic covariates and variable baseline risk. Time since first reporting vaccination, age, race-ethnicity, region, and calendar time were statistically significant predictors of incident infection. Studies of VE during periods of Delta and Omicron spread are underway. Coronavirus disease 2019 vaccines have a critical role in preventing symptomatic illness, including 22 serious disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] , and in reducing viral 23 transmission [2] . COVID-19 vaccines approved or authorized for emergency use in the US by the Food and Drug 24 Administration had high efficacy against severe disease in Phase III trials, ranging from 67% to 95% [1, [3] [4] [5] . However, 25 long-term management of the SARS-CoV-2 pandemic remains a substantial challenge, especially as variants of concern 26 emerge. To inform public health policy, it is critical to monitor real-world effectiveness of COVID-19 vaccines at the 27 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 2 population-level over longer periods of time [6] . Numerous individual-level and environmental factors (e.g., local 1 community transmission, social distancing and other mitigation practices, vaccine type, and vaccination coverage) impact 2 vaccine effectiveness (VE), underscoring the importance of and need for population-based studies of VE against SARS-3 CoV-2 infection. Evaluating VE is challenging given the multitude of endpoints relevant to SARS-CoV-2 infection. Many COVID-5 19 VE studies have evaluated severe endpoints, such as mortality and hospitalizations, often in higher risk populations. Mild 6 and asymptomatic infections likely account for the vast majority of SARS-CoV-2 infections, with serosurveys indicating 7 that many more infections occur than diagnosed cases [7] . Vaccine breakthrough infections are frequently asymptomatic 8 with one study finding that among >10,000 breakthrough infections, over a quarter were asymptomatic [8] . Asymptomatic 9 individuals (including with vaccine breakthrough infections) can transmit SARS-CoV-2 to others, and thus preventing 10 asymptomatic infection is important to decrease widespread community transmission [9] . Therefore, VE against acquiring 11 infection is important to assess. Constraints on large-scale population-level monitoring of VE include the cost and logistical challenges of enrolling 13 and following cohorts of vaccinated and unvaccinated individuals, and laboratory assays. Molecular diagnostic assays, such 14 as reverse transcription polymerase chain reaction (rtPCR) assays applied to respiratory swab samples, are the gold standard 15 for diagnosing SARS-CoV-2 infection. However, molecular diagnostic assays have a limited detection window, 16 necessitating frequent follow-up that reduces the feasibility of ongoing large-scale surveillance, higher cost, and lower 17 throughput. In contrast, serological assays that detect binding antibodies (Abs) against the Spike (S) and Nucleocapsid (NC) 18 viral proteins are lower cost, higher throughput, and can identify SARS-CoV-2 infections after resolution. We estimated VE using a retrospective cohort study among repeat blood donors who donated during the first half 20 of 2021 at Vitalant, a major US blood collection organization (BCO). This proof-of-concept study demonstrates a viable 21 approach for continued near real-time monitoring of VE via serological surveillance among repeat blood donors. Beginning in June 2020, Vitalant tested all donors for anti-S and anti-NC Abs using the Ortho VITROS anti-SARS-24 CoV-2 S Total Ig and Roche Elecsys® NC Anti-SARS-CoV-2 assays. For this analysis, we included donations from donors 25 who donated at least twice between January 1 to July 6, 2021, with anti-S and anti-NC test results. Donors self-reported any 26 COVID-19 vaccination (vaccine type and number of doses not specified) at each donation via the Donor Health 27 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101 doi: medRxiv preprint 1 serological and COVID-19 vaccination status. Specifically, we defined an interdonation interval as vaccinated time at risk 2 if the donor was vaccinated and had anti-S Abs but not anti-NC Abs at the first timepoint and unvaccinated time at risk if 3 the donor was not vaccinated at both timepoints and had no anti-S Abs at the first timepoint. Interdonation intervals where 4 donors were infected (anti-NC positive) at the start were excluded. Additionally, intervals during which vaccination took 5 place were excluded because the proportion of vaccinated versus unvaccinated time could not be determined. A single donor 6 could contribute both unvaccinated and vaccinated time at risk. Exact dates of vaccination and vaccine manufacturer were 7 not recorded on the DHQ responses, although preliminary data from a survey of Vitalant blood donors conducted 8 subsequently indicates that more than 90% received an mRNA vaccine (Moderna or Pfizer-BioNTech). Incident SARS-9 CoV-2 infections were identified using anti-NC seroconversion; vaccine breakthrough infection defined as seroconversion 10 after self-report of COVID-19 vaccination. We used multivariable regression to evaluate the association between incident SARS-CoV-2 infection rate and During the study period, vaccine availability and uptake increased rapidly in the blood donor population and SARS-25 CoV-2 incidence declined rapidly during the early months of 2021. This raised a concern of potential bias in VE estimates 26 caused by unvaccinated time at risk accumulating disproportionately during a period when baseline risk of acquiring the 27 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 4 infection was higher, which could lead to an overestimate of the protective effect of vaccination. We conducted an extensive 1 sensitivity analysis using simulated data to evaluate bias across VE estimation approaches and inform model selection. We 2 simulated 1,020 datasets similar to the Vitalant repeat donor dataset, with varying rates of declining incidence, rates of 3 increasing vaccination, and proportions of the population vaccinated by the end of the period. We evaluated several VE 4 estimation methods and data selection rules, including unadjusted incidence rate ratios (IRRs) based on conventional person-5 time methods (naïve analysis), Cox proportional hazards regression on a calendar timescale, and Poisson regression adjusted 6 for calendar time; methods were assessed for absolute and relative bias and precision (see Supplementary Appendix). Table 1 ). The number of days that the donor had been vaccinated at the start of the 18 final interval was significant and protective. Age, race-ethnicity, geographic region and the month during which a donor's 19 follow-up ended were statistically significant predictors of incident infection, though sex was not (Supplementary Table 1 ). The naïve analysis yielded an unadjusted VE estimate of 92.5% (90.8%-93.8%, Table 1 ), although our simulation study 21 found a substantial risk of bias. VE against acquiring any serologically identifiable SARS-CoV-2 infection, was high in blood donors during the 24 first half of 2021 at 88.8%. Our VE estimate was comparable to previous VE estimates in studies evaluating protection 25 against SARS-CoV-2 infection based on detection of viral RNA in swab samples, which ranged from 73% to 98.2% [10-26 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 12], and mostly lower than estimates of protection against hospitalization, which ranged from 88.0% to 95.1% [10, 13, 14] . Several limitations need to be considered when interpreting these results. The serological assays employed in this 14 study have high sensitivity and specificity for past infection and vaccination-induced Abs, but lower sensitivity than 15 molecular assays for acute infection. We did not have detailed information on COVID-19 vaccination timing, number of 16 doses, or vaccine type, and there is the potential for misreporting of vaccination status by donors on the DHQ. To limit the 17 impact of potential misclassification of vaccination status, we required serological evidence of a vaccination response 18 (presence of anti-S Abs and absence of anti-NC Abs) to corroborate self-reported vaccination, although donors could still 19 have been classified as vaccinated after receiving only the first of a two-dose series or not long enough after receiving a 20 single-dose vaccine or the second dose of a two-dose series to have developed robust Ab responses and be considered fully 21 vaccinated. Sporadic presentation for donation, which for some donors may be very infrequent, is inherent to repeat blood 22 donation datasets. We developed methods to account for interval censoring of both vaccination and infection events, but 23 some data were excluded because vaccination status or the ordering of vaccination and infection events was uncertain during 24 the interval. We used Vitalant region as a proxy geographic variable, however this may not capture with adequate granularity 25 the heterogeneity in local transmission. Blood donors are not representative of the US population-e.g., racial/ethnic 26 minorities are underrepresented, and donors tend to be healthier than the general population-but there is no reason to expect 27 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 6 that these differences are more pronounced in vaccinated or unvaccinated donors. Lastly, these data were collected before All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101 doi: medRxiv preprint 1 We conducted a simulation study to evaluate vaccine effectiveness (VE) estimation methods and data inclusion 2 rules with respect to bias and precision, with a particular focus on the bias that may arise in observational studies when both 3 incidence and the proportion of the population vaccinated changes rapidly during the study period. During the first half of 4 2021, the proportion of blood donors who were vaccinated increased from close to zero to approximately 80%, while over 5 the same period incidence declined rapidly from a peak around the 2020/2021 holiday period, and then stabilized prior to 6 the Delta variant-driven outbreak. In this situation, unvaccinated follow-up time accumulates disproportionately during a 7 period when background incidence (and therefore baseline risk of infection acquisition) was relatively high, and vaccinated 8 follow-up time disproportionately during a period of relatively low incidence. Methods that do not appropriately account 9 for variable baseline risk would likely be biased and result in an overestimate of VE. We simulated 1,020 datasets that reflected donations during a 360-day period ( = −180 to = 180), with vaccines 11 implemented during the second 180 days (from = 0). The simulations represent an idealized scenario of rapid vaccine 12 uptake and rapid incidence decline during the period of vaccine uptake in order to pressure-test data selection rules and 13 estimation methods. The first 180 days are included in the simulation in order to effectively reflect the entire history of the 14 pandemic in this simulated population without the need to specify sensible initial conditions, and mirroring the one-year 15 period of universal SARS-CoV-2 antibody testing by Vitalant from June 2020 to early July 2021. Each dataset consisted of 200,000 donation intervals with the time of the first donation drawn from a uniform 17 distribution [−180,180] , and the length of the donation interval drawn from a truncated normal distribution ( = 65, = 18 35), with 90% of donations set to be from whole blood donors with a minimum inter-donation interval of 56 days, and 10% 19 from apheresis donors with a minimum inter-donation interval of 7 days. All intervals had a maximum length of 180 days. Intervals that ended after = 180 were excluded from analysis. Incidence during the first 180 days (i.e., preceding the 21 period of interest during which vaccination was implemented) was a function of time designed to reflect multiple epidemic 22 waves, culminating in a fixed peak incidence at day 0 of 50 infections per 10,000 person-weeks (see Figure A1 ). During the 23 period of interest, incidence was an exponentially declining function of time, eventually plateauing at 20% of peak incidence 24 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 (i.e., at 10 cases per 10,000 person-weeks). The function for incidence during the pre-vaccination period was a simple spline 1 function, while the exponential decline during the period of interest is given by the following equation: 2 ( ) = + ( − ) − 3 with time, the plateau value or asymptote, the initial value, and the exponential rate. The exponential rate of decline 4 was varied stochastically in each simulation, drawn from a uniform distribution [40, 80] . The proportion of the donor 5 population that was vaccinated was kept fixed at zero until day 0, after which it exponentially increased (using the same 6 function as above), at a rate also drawn from the uniform distribution [40, 80] , and plateauing at 80% ( Figure A2 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101 doi: medRxiv preprint 1 interval by evaluating the incidence function at the midpoint of the interval (expressed in infections per person-day) 2 multiplied by the size of the interval to obtain a total risk of infection over the course of the interval. There is a loss of 3 granularity compared to formally computing a cumulative probability of infection during an interval by integrating over 4 time-varying incidence over the interval, but we did not believe this loss of resolution to be relevant for the purposes of this 5 simulation study. This probability was then used to draw whether an infection took place from a binomial distribution. Similarly, the probability that the donor was vaccinated at the start of the interval ( 1 ) was obtained by evaluating 7 the vaccination proportion function at 1 , and the probability at the end of the interval by evaluating the function at 2 , given 8 that the donor was unvaccinated at 1 , with vaccination status at 1 and 2 set binomially. If vaccination occurred during the 9 interval, the status would be different at 1 and 2 . Vaccine efficacy was set for each simulation run at a value between 30% and 90% (drawn from a uniform 11 distribution), and then applied to the infection probability computed as in unvaccinated donors. The probability of infection 12 during unvaccinated and vaccinated intervals 1 to 2 are therefore given by: The first critical question faced in data analysis is which data points to include. In the case of these repeat donor 16 data, we sought to determine: (1) whether to include data from the pre-vaccination period in analysis and (2) how best 17 handle intervals during which a donor's vaccination status changed. The latter concern arises from the fact that these data 18 are interval censored, so that the time of an event is not precisely knownonly whether it had already occurred at the time 19 of donation. This is of particular concern since vaccination had a strong time dependence and was rapidly increasing over 20 the period, and therefore an unobserved vaccination event during an interval would not have had a uniform likelihood to 21 have occurred at all times in the interval. If a donor was vaccinated during an interval and did not become infected during 22 that interval, it is not clear how to allocate time-at-risk in incidence calculations. If a donor was both vaccinated and became 23 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 14 infected during an interval, it cannot be known in which order the events occurred. We evaluated the following strategies 1 with respect to intervals during which vaccination took place: We considered a method based on estimating incidence in vaccinated an unvaccinated donors, computing an 7 incidence rate ratio (IRR) and then calculating VE as 1-IRR. This method does not account for variable baseline risk and 8 cannot be adjusted for confounding (such as demographic differences associated with risk in the vaccinated and 9 unvaccinated groups). We further considered two regression approaches: Cox proportional hazards regression, which is a 10 time-to-event approach frequently used for studies of this kind, and Poisson regression, which is frequently used for 11 incidence analysis when adjustment for covariates is necessary. Cox models were fit to data on a calendar timescale. Poisson 12 models treated exposure time as an offset (the entire interval if no infection took place, and half the interval if infection took 13 place) and used a log link. While the Cox model allows for an unspecified time-varying baseline hazard, and therefore 14 theoretically should not be exposed to the potential bias arising from vaccinated exposure time accumulating 15 disproportionately during a lower-incidence period, we tested both Cox and Poisson models with and without calendar time 16 as a covariate, to control for varying baseline hazard. In general, data selection rules that kept only intervals that started during the vaccination era (i.e. 1 ≥ 0) had lower 18 bias. It is also intuitively apparent that additional unvaccinated exposure time during a period when no vaccinated exposure 19 time accumulated does not add relevant information to the analysis. We therefore concluded that using only intervals with 20 a first donation on or after 1 January 2021 was appropriate. In these simulated scenarios, the approach to handling intervals 21 during which vaccination took place had a small effect. However, since we used incidence at the time of the midpoint of an 22 interval to determine the probability of infection during the interval, an equal allocation of these intervals to vaccinated and 23 unvaccinated exposure time may appear safer than it would be in reality during rapidly changing incidence. We therefore 24 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101 doi: medRxiv preprint 1 Supplementary White, Non-Hispanic ref Progress of the COVID-19 vaccine effort: viruses, vaccines 3 and variants versus efficacy, effectiveness and escape Community transmission and viral load kinetics of the SARS-CoV-2 delta 5 (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. The 6 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 Real world effectiveness of covid-19 vaccines Estimated US Infection-and Vaccine-Induced SARS-CoV-2 Seroprevalence 15 Based on Blood Donations COVID-19 Vaccine Breakthrough Infections Reported to CDC -United States Transmission of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-19 CoV-2) from pre and asymptomatic infected individuals: a systematic review Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a 21 large integrated health system in the USA: a retrospective cohort study All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 End of follow-up All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022